Page 4 - Evolve Biosystems News Today

Share this article DAVIS, Calif., March 11, 2021 /PRNewswire/ -- Evolve BioSystems, Inc. today announces that its product, activated B. infantis EVC001, will be used in one of the largest international clinical studies on preventing type 1 diabetes (T1D) in genetically predisposed children.  The randomized, controlled, double-blind, multicenter trial will be conducted across eight major research centers in five European countries. The Leona M. and Harry B. Helmsley Charitable Trust is fundi...

Day One highlights Microbiome through life: Exploring new science and commercial strategies from the first 1,000 days to healthy aging. The day features Francesco Asnicar, University of Trento; John Deaton, Deerland Probiotics & Enzymes; Jennifer Gu, AIDP, Inc; Lindsay Hall, Quadram Institute and the Technical University of Munich; David Kyle, Evolve BioSystems, Inc.; Stephen Lindemann, Purdue University and Nathan Price, Institute for Systems Biology and Onegevity Health. Day Two will look a...

Investing in the Future of Food: Manna Tree investors seek emerging brands focused on human health As the ongoing pandemic accelerates consumer interest in the role of nutrition in wellness and underscores the supply chain’s fragility, the investors at Manna Tree Partners are looking for at least three growth stage companies that are revolutionizing the production, delivery and consumption of food to support human health. With $235 million in assets under its mana...

Pre-term infants fed with B. Infantis experienced lower level of intestinal inflammation Researchers publishing in the peer-review journal Frontiers in Pediatrics report that pre-term infants fed Bifidobacterium longum subsp. infantis (activated B. infantis EVC001) experienced significantly lower level of intestinal inflammation, 62% less diaper rash, and required 62% fewer antibiotics- all of which are critical health indicators in neonatal care. The study, Impact of probiotic B. infantis E...

Dairy Dialog podcast 121: Tate & Lyle, Evolve Biosystems, Bridge Cheese Dairy Dialog podcast 121: Tate & Lyle, Evolve Biosystems, Bridge Cheese This week we feature three interviews, with five guests. We have conversations with Timothy Brown, CEO of Evolve BioSystems and Pam Shepherd, managing director of Manna Tree; Jim Carr, PhD, director, sweeteners global ingredient technology and Abigail Storms, vice president of sweetener innovation at Tate & Lyle; and Michael ...

B. infantis EVC001 on key health indicators specifically in pre-term infants. The work was conducted at two neonatal intensive care units (NICU) in Southern California. "Neonatologists, neonatal nurses and other hospital-based clinical staff are acutely focused on affecting the factors that positively impact quality of care and length of stay among pre-term infants," said Dr. Karl Sylvester, Pediatric Surgeon, Stanford, California. "This study provides compelling evidence that feeding B. inf...

Evolve BioSystems gets $55 million investment led by Cargill Evolve BioSystems has announced $55 million in funding from Cargill and a private equity firm to bring its infant probiotic to market scale. Evolve Biosystems is an independent microbiome research company that was launched out of University of California, Davis in 2014. It was initially funded  by the Bill & Melinda Gates Foundation. Also participating in the funding announced this week was investment firm...

Evolve BioSystems Announces Major Strategic Investment from Cargill and Manna Tree to Support Innovative Probiotic That Dramatically Improves Infant Gut Health Evolves innovative probiotic addresses widespread Newborn Gut Deficiency by restoring key bacteria in the infant gut microbiome News provided by Share this article Share this article DAVIS, Calif., Feb. 8, 2021 /PRNewswire/ -- Evolve BioSystems announced today that it completed a substantial first close in a $55 million Series D round o...